TrialScientific reports2022

Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection.

Mathilde Choteau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.